Table 1 Clinical characteristics of patients received first FLT3i in the frontline (cohort 1) and relapse/refractory (cohort 2) settings
From: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Baseline clinical features | Cohort 1 (n = 56) | Cohort 2 (n = 183) |
|---|---|---|
Median [range], number or positive/tested (%) | ||
Age, median (range) | 62 [22–90] | 65 [21–89] |
Age ≥ 60 | 30 (54%) | 107 (60%) |
Sex, Male | 29 (51%) | 100 (56%) |
sAML | 3 (6%) | 44 (24%) |
Karyotype | ||
Diploid | 36 (64%) | 68 (37%) |
Monosomy 5/7 | 3 (5%) | 16 (9%) |
Trisomy 8 | 1 (2%) | 14 (8%) |
11q23-rearrangement | 0 (0) | 6 (3%) |
Miscellaneous | 15 (27%) | 65 (35%) |
Insufficient metaphases | 1 (2%) | 14 (8%) |
Mutations | ||
NPM1 | 17/43 (39%) | 35/81 (43%) |
DNMT3A | 10/22 (45%) | 21/69 (30%) |
RUNX1 | 3/14 (21%) | 9/51 (18%) |
TET2 | 4/14 (29%) | 8/31 (26%) |
WT1 | 0/14 (0) | 10/49 (20%) |
CEBPA | 3/20 (15%) | 10/69 (14%) |
RAS | 4/30 (13%) | 9/77 (12%) |
TP53 | 0/19 (0%) | 4/64 (6%) |
ASXL1 | 1/14 (7%) | 6/43 (14%) |
IDH1 | 1/22 (5%) | 5/64 (8%) |
IDH2 | 4/22 (18%) | 7/70 (10%) |
PTPN11 | 1/18 (6%) | 4/64 (6%) |
GATA2 | 0/14(0%) | 1/49 (2%) |
KIT | 1/27(4%) | 3/67 (4%) |
Frontline therapy with a FLT3i | 56 | 0 |
CCT + FLT3i | 33 (59%) | 0 |
LIT + FLT3i | 22 (39%) | 0 |
Single-agent FLT3i | 1 (2%) | 0 |
Number of therapies prior to first FLT3i exposure | 0 | 2 |
Total FLT3i exposures (events) in salvage | 40 | 301 |
CCT + FLT3i | 9 (22%) | 43 (14%) |
LIT + FLT3i | 10 (25%) | 113 (38%) |
Single-agent FLT3i | 21 (53%) | 145 (48%) |
Total sequential FLT3i exposure (sequential events) | 40 | 118 |